Innate immune mechanisms in vitiligo: Danger from within

Current Opinion in Immunology

Volumn 25, Issue 6, 2013, Pages 676-682

  Richmond, Jillian M ^a   Frisoli, Michael L ^a   Harris, John E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ADAPTIVE IMMUNITY; ALLELE; CELL STRESS; DEPIGMENTATION; DISEASE COURSE; GENETIC ASSOCIATION; GENETICS; HUMAN; INNATE IMMUNITY; MELANOCYTE; PATHOGENESIS; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; VITILIGO;

ADAPTIVE IMMUNITY; ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; STRESS, PHYSIOLOGICAL; VITILIGO;

EID: 84889080986     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.10.010     Document Type: Review

References (66)

1. Ongenae K., Beelaert L., van Geel N., Naeyaert J.M. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006, 20:1-8.
2. Alikhan A., Felsten L.M., Daly M., Petronic-Rosic V. Vitiligo: a comprehensive overview Part I Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011, 65:473-491.
3. Spritz R.A. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2012, 132:268-273.
4. Schallreuter K.U., Bahadoran P., Picardo M., Slominski A., Elassiuty Y.E., Kemp E.H., Giachino C., Liu J.B., Luiten R.M., Lambe T., et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. Exp Dermatol 2008, 17:139-140. discussion 141-160.
5. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Das P.K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996, 148:1219-1228.
6. van den Wijngaard R., Wankowicz-Kalinska A., Le Poole C., Tigges B., Westerhof W., Das P. Local immune response in skin of generalized vitiligo patients Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000, 80:1299-1309.
7. Ogg G.S., Rod Dunbar P., Romero P., Chen J.L., Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998, 188:1203-1208.
8. Wankowicz-Kalinska A., van den Wijngaard R.M., Tigges B.J., Westerhof W., Ogg G.S., Cerundolo V., Storkus W.J., Das P.K. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003, 83:683-695.
9. van den Boorn J.G., Konijnenberg D., Dellemijn T.A., van der Veen J.P., Bos J.D., Melief C.J., Vyth-Dreese F.A., Luiten R.M. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
10. Palermo B., Campanelli R., Garbelli S., Mantovani S., Lantelme E., Brazzelli V., Ardigo M., Borroni G., Martinetti M., Badulli C., et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001, 117:326-332.
11. Okamoto T., Irie R.F., Fujii S., Huang S.K., Nizze A.J., Morton D.L., Hoon D.S. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998, 111:1034-1039.
12. Kemp E.H., Waterman E.A., Gawkrodger D.J., Watson P.F., Weetman A.P. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998, 139:798-805.
13. Gregg R.K., Nichols L., Chen Y., Lu B., Engelhard V.H. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol 2010, 184:1909-1917.
14. Harris J.E., Harris T.H., Weninger W., Wherry E.J., Hunter C.A., Turka L.A. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol 2012, 132:1869-1876.
15. Lambe T., Leung J.C., Bouriez-Jones T., Silver K., Makinen K., Crockford T.L., Ferry H., Forrester J.V., Cornall R.J. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions. J Immunol (Baltimore, MD: 1950) 2006, 177:3055-3062.
16. Overwijk W.W., Lee D.S., Surman D.R., Irvine K.R., Touloukian C.E., Chan C.C., Carroll M.W., Moss B., Rosenberg S.A., Restifo N.P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999, 96:2982-2987.
17. Klarquist J., Denman C.J., Hernandez C., Wainwright D.A., Strickland F.M., Overbeck A., Mehrotra S., Nishimura M.I., Le Poole I.C. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010, 23:276-286.
18. Tu C.X., Jin W.W., Lin M., Wang Z.H., Man M.Q. Levels of TGF-beta(1) in serum and culture supernatants of CD4(+)CD25 (+) T cells from patients with non-segmental vitiligo. Arch Dermatol Res 2011, 303:685-689.
19. Lili Y., Yi W., Ji Y., Yue S., Weimin S., Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012, 7:e37513.
20. Zhou L., Li K., Shi Y.L., Hamzavi I., Gao T.W., Henderson M., Huggins R.H., Agbai O., Mahmoud B., Mi X., et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res 2012, 25:602-611.
21. Puri N., Mojamdar M., Ramaiah A. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects. J Invest Dermatol 1987, 88:434-438.
22. Jimbow K., Chen H., Park J.S., Thomas P.D. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001, 144:55-65.
23. Maresca V., Roccella M., Roccella F., Camera E., Del Porto G., Passi S., Grammatico P., Picardo M. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997, 109:310-313.
24. Boissy R.E., Liu Y.Y., Medrano E.E., Nordlund J.J. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991, 97:395-404.
25. Schallreuter K.U., Moore J., Wood J.M., Beazley W.D., Gaze D.C., Tobin D.J., Marshall H.S., Panske A., Panzig E., Hibberts N.A. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 1999, 4:91-96.
26. Shalbaf M., Gibbons N.C., Wood J.M., Maitland D.J., Rokos H., Elwary S.M., Marles L.K., Schallreuter K.U. Presence of epidermal allantoin further supports oxidative stress in vitiligo. Exp Dermatol 2008, 17:761-770.
27. Koca R., Armutcu F., Altinyazar H.C., Gurel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol 2004, 29:406-409.
28. Oliver E.A.S.L., Warren L.H. Occupational leukoderma. JAMA 1939, 113:927-928.
29. Mosher D.B., Parrish J.A., Fitzpatrick T.B. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977, 97:669-679.
30. Ghosh S., Mukhopadhyay S. Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country. Br J Dermatol 2009, 160:40-47.
31. van den Boorn J.G., Picavet D.I., van Swieten P.F., van Veen H.A., Konijnenberg D., van Veelen P.A., van Capel T., Jong E.C., Reits E.A., Drijfhout J.W., et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol 2011, 131:1240-1251.
32. Toosi S., Orlow S.J., Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 2012, 132:2601-2609.
33. Meyskens F.L., Farmer P., Fruehauf J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001, 14:148-154.
34. Shi F., Kong B.W., Song J.J., Lee J.Y., Dienglewicz R.L., Erf G.F. Understanding mechanisms of vitiligo development in Smyth line of chickens by transcriptomic microarray analysis of evolving autoimmune lesions. BMC Immunol 2012, 13:18.
35. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:332-333.
36. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837.
37. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140.
38. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
39. Mosenson J.A., Zloza A., Klarquist J., Barfuss A.J., Guevara-Patino J.A., Poole I.C. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res 2012, 25:88-98.
40. Denman C.J., McCracken J., Hariharan V., Klarquist J., Oyarbide-Valencia K., Guevara-Patino J.A., Le Poole I.C. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol 2008, 128:2041-2048.
41. Mosenson J.A., Zloza A., Nieland J.D., Garrett-Mayer E., Eby J.M., Huelsmann E.J., Kumar P., Denman C.J., Lacek A.T., Kohlhapp F.J., et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med 2013, 5:174ra128.
42. Bang C., Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 2012, 44:2060-2064.
43. Thulasingam S., Massilamany C., Gangaplara A., Dai H., Yarbaeva S., Subramaniam S., Riethoven J.J., Eudy J., Lou M., Reddy J. miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem 2011, 352:181-188.
44. Gastpar R., Gehrmann M., Bausero M.A., Asea A., Gross C., Schroeder J.A., Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 2005, 65:5238-5247.
45. Yu R., Broady R., Huang Y., Wang Y., Yu J., Gao M., Levings M., Wei S., Zhang S., Xu A., et al. Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLoS One 2012, 7:e51040.
46. Long E.O., Rajagopalan S. Stress signals activate natural killer cells. J Exp Med 2002, 196:1399-1402.
47. Spritz R.A. Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol 2013, 40:310-318.
48. Roychoudhuri R., Hirahara K., Mousavi K., Clever D., Klebanoff C.A., Bonelli M., Sciume G., Zare H., Vahedi G., Dema B., et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013, 498:506-510.
49. Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., Nieuwenhuis E.E., Higgins D.E., Schreiber S., Glimcher L.H., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-756.
50. Erener S., Petrilli V., Kassner I., Minotti R., Castillo R., Santoro R., Hassa P.O., Tschopp J., Hottiger M.O. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes. Mol Cell 2012, 46:200-211.
51. Spritz R.A. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010, 2:78.
52. Eizirik D.L., Miani M., Cardozo A.K. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 2013, 56:234-241.
53. Cotter M.A., Thomas J., Cassidy P., Robinette K., Jenkins N., Florell S.R., Leachman S., Samlowski W.E., Grossman D. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res 2007, 13:5952-5958.
54. Yu N., Zhang S., Zuo F., Kang K., Guan M., Xiang L. Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. J Dermatol Sci 2009, 56:113-120.
55. Margariti A., Li H., Chen T., Martin D., Vizcay-Barrena G., Alam S., Karamariti E., Xiao Q., Zampetaki A., Zhang Z., et al. XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation. J Biol Chem 2013, 288:859-872.
56. Fader C.M., Sanchez D.G., Mestre M.B., Colombo M.I. TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. Biochim Biophys Acta 2009, 1793:1901-1916.
57. Adler V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104-6111.
58. Pawaria S., Binder R.J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2011, 2:521.
59. Basu S., Binder R.J., Suto R., Anderson K.M., Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000, 12:1539-1546.
60. Tal M.C., Sasai M., Lee H.K., Yordy B., Shadel G.S., Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci U S A 2009, 106:2770-2775.
61. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692.
62. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183:3170-3176.
63. Cooper M.A., Fehniger T.A., Ponnappan A., Mehta V., Wewers M.D., Caligiuri M.A. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur J Immunol 2001, 31:792-801.
64. Chaix J., Tessmer M.S., Hoebe K., Fuseri N., Ryffel B., Dalod M., Alexopoulou L., Beutler B., Brossay L., Vivier E., et al. Cutting edge: Priming of NK cells by IL-18. J Immunol 2008, 181:1627-1631.
65. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
66. Kumar H., Koyama S., Ishii K.J., Kawai T., Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 2008, 180:683-687.